Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10962324 | Vaccine | 2016 | 6 Pages |
Abstract
It was demonstrated that pre-existing BVDV-1 antibodies do not impact on the efficacy of live attenuated vaccines against CSF. Both C-strain “Riems” and marker vaccine “CP7_E2alf” were able to confer full protection against highly virulent challenge seven days after vaccination. However, slight interference was seen with serological DIVA diagnostics accompanying the vaccination with CP7_E2alf. Amended sample preparation and combination of test systems was able to resolve most cases of false positive reactions. However, in such a co-infection scenario, optimization and embedding in a well-defined surveillance strategy is clearly needed.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Carolin Dräger, Charlotte Schröder, Patricia König, Birthe Tegtmeyer, Martin Beer, Sandra Blome,